Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Do DTC Television Ads Really Need To List All Drug Risks?

This article was originally published in The Pink Sheet Daily

Executive Summary

FDA study aims to determine the impact of limiting Rx drug risk info in TV ads to those that are “serious and actionable.”

You may also be interested in...



Less Is More: FDA May Narrow Risk Info In Rx Drug TV Ads

Agency is considering whether drug broadcast ads should note only risks that are severe, serious or actionable; FDA study finds this limitation improves risk recall and recognition of benefits.

Rx Ad Studies Target Risk Info Location, Efficacy Framing, Oncology Products

Flurry of new studies brings tally of FDA research projects on Rx drug promotion to 43; the 14 in progress and 7 pending peer review or recently published have a total cost of $15.5m.

DTC Study Shows Limited Risk Statement Works, But Will Pharma Ad Practices Change?

Viewers retain more risks and benefits in DTC ads showing only limited risk information, but experts predict it may not result in substantial change right away.

Related Content

Topics

UsernamePublicRestriction

Register

OM000882

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel